Shares of Quest Diagnostics Inc. DGX rallied 2.27% to $175.56 Friday, on what proved to be an all-around great trading ...

Shares of Quest Diagnostics Inc. DGX slid 1.71% to $172.01 Wednesday, on what proved to be an all-around positive trading ...

Citigroup cut shares of Quest Diagnostics (NYSE:DGX – Free Report) from a buy rating to a neutral rating in a report ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

Quest Diagnostics DGX has achieved impressive growth over the past year, with its shares rising 38%. It has outperformed the industry’s 7.7% rise and the S&P 500 composite’s 17.1% gain. Presently ...

A Wall Street analyst issued contrasting ratings on Tuesday for two major diagnostic testing companies, upgrading shares of ...

Fresenius Medical Care plans to sell select assets of Spectra Laboratories to Quest Diagnostics as it exits non-core markets.

Evercore ISI analyst Elizabeth Anderson CFA maintained a Hold rating on Quest Diagnostics (DGX – Research Report) yesterday and set a price ...

Citi downgraded Quest Diagnostics (DGX) to Neutral from Buy with an unchanged price target of $185. The firm believes Quest is well positioned ...

In an age of capitation and value-based care, health plans must work harder than ever to offer tailored support to higher-risk members with chronic conditions.

Quest Diagnostics DGX has achieved impressive growth over the past year, with its shares rising 38%. It has outperformed the industry’s 7.7% rise and the S&P 500 composite’s 17.1% gain.